Physician profile
Grant Meyer
NPI 1174900823
$3,873.23
in general payments reported to CMS, 2019-2025
46 companies · $930 in 2025
The $930 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $234 · 2021: $348 · 2022: $877 · 2023: $681 · 2024: $695 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,306.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $407.02 | 2019-2025 | Mounjaro, Kisunla, Jardiance |
| Pfizer INC. | $366.68 | 2021-2025 | |
| Abbvie INC. | $344.32 | 2021-2025 | |
| Novo Nordisk INC | $294.89 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $245.39 | 2022-2025 | Bexsero, Trelegy Ellipta, Penmenvy |
| Antares Pharma, INC. | $169.88 | 2020-2022 | |
| Sanofi Pasteur INC. | $144.24 | 2024-2025 | |
| Astellas Pharma US INC | $140.04 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.45 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Boston Scientific Corporation | $126.81 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Amarin Pharma, INC. | $113.62 | 2019-2020 | |
| Seqirus USA INC | $100.35 | 2021-2025 | Flucelvax, Fluad, Fluad Quadrivalent |
| Janssen Pharmaceuticals, INC | $88.53 | 2023 | Xarelto, Spravato |
| Abbott Laboratories | $85.13 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $84.64 | 2021-2024 | Rexulti |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.